[go: up one dir, main page]

IL104192A - Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient - Google Patents

Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient

Info

Publication number
IL104192A
IL104192A IL104192A IL10419292A IL104192A IL 104192 A IL104192 A IL 104192A IL 104192 A IL104192 A IL 104192A IL 10419292 A IL10419292 A IL 10419292A IL 104192 A IL104192 A IL 104192A
Authority
IL
Israel
Prior art keywords
dosage form
pharmaceutical dosage
active ingredient
optionally
form according
Prior art date
Application number
IL104192A
Other languages
English (en)
Other versions
IL104192A0 (en
Original Assignee
Siegfried Ag Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siegfried Ag Pharma filed Critical Siegfried Ag Pharma
Publication of IL104192A0 publication Critical patent/IL104192A0/xx
Publication of IL104192A publication Critical patent/IL104192A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
IL104192A 1992-02-17 1992-12-21 Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient IL104192A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH46492 1992-02-17

Publications (2)

Publication Number Publication Date
IL104192A0 IL104192A0 (en) 1993-05-13
IL104192A true IL104192A (en) 1998-01-04

Family

ID=4187618

Family Applications (1)

Application Number Title Priority Date Filing Date
IL104192A IL104192A (en) 1992-02-17 1992-12-21 Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient

Country Status (12)

Country Link
US (1) US5439687A (sk)
JP (1) JPH061716A (sk)
CA (1) CA2086989A1 (sk)
CZ (1) CZ285177B6 (sk)
FI (1) FI930657A (sk)
HU (1) HU222252B1 (sk)
IL (1) IL104192A (sk)
MX (1) MX9300664A (sk)
NO (1) NO302216B1 (sk)
PL (1) PL172361B1 (sk)
RU (1) RU2122413C1 (sk)
SK (1) SK9793A3 (sk)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
JP2676319B2 (ja) * 1994-02-09 1997-11-12 大洋薬品工業株式会社 塩酸ニカルジピンの徐放剤用製剤およびこれを利用した徐放化製剤
JP3148256B2 (ja) 1996-07-08 2001-03-19 エドワード メンデル カンパニー．，インコーポレーテッド 高用量難溶性薬物用持続放出マトリックス
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
CA2352211C (en) * 1999-09-30 2009-03-24 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
KR100379299B1 (ko) * 2000-01-15 2003-04-10 주식회사 중외제약 펠로디핀의 가용화 방법 및 방출제어형 제제
US20030180354A1 (en) * 2001-10-17 2003-09-25 Dr. Reddy's Laboratories Limited Amlodipine maleate formulations
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
BE1014922A3 (nl) * 2002-03-01 2004-06-01 Pfizer Ltd Amlodipine als vrije base.
MXPA04009701A (es) * 2002-04-05 2005-05-27 Penwest Pharmaceuticals Co Formulaciones de metoprolol de liberacion sostenida.
EP1364644B1 (en) * 2002-05-21 2008-09-17 Watson Laboratories, Inc. Pharmaceutical formulation with extended release
JP4563642B2 (ja) * 2002-05-31 2010-10-13 ワトソン ラボラトリーズ、インコーポレイテッド 医薬製剤
US20040127978A1 (en) * 2002-08-13 2004-07-01 Medtronic, Inc. Active agent delivery system including a hydrophilic polymer, medical device, and method
CN1929827A (zh) * 2004-01-14 2007-03-14 拉维法姆实验室股份有限公司 包含至少一种脂肪酸的用于二氢吡啶类钙拮抗剂的经皮递送装置
EP1748762B1 (de) * 2004-05-28 2013-12-18 AbbVie Deutschland GmbH & Co KG Dosierungsform, erhältlich aus einer ein anorganisches pigment umfassenden pulvermischung
US20060210623A1 (en) * 2005-03-17 2006-09-21 Stach Paul E Sustained release delivery of isradipine
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
US20070128280A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
ES2547226T5 (es) * 2006-08-30 2020-06-12 Jagotec Ag Formulaciones de dosificación oral de liberación controlada que comprenden un núcleo y una o más capas de barrera
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
EP2124552A4 (en) * 2007-01-31 2013-01-09 Methylation Sciences Internat Srl PHARMACEUTICAL FORMULATIONS WITH PROLONGED RELEASE OF S-ADENOSYLMETHIONINE
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
JP4864024B2 (ja) * 2008-02-15 2012-01-25 エスエス製薬株式会社 時限放出製剤
KR20100069170A (ko) * 2008-12-16 2010-06-24 삼일제약주식회사 라시디핀 함유 과립 및 이를 포함하는 약학 조성물
KR101136075B1 (ko) * 2009-06-30 2012-04-17 케이엘피앤지씨앤팜 주식회사 고혈압 치료제 조성물
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
PL389530A1 (pl) 2009-11-10 2011-05-23 Fabryka Maszyn FAMUR Spółka Akcyjna Sposób przeniesienia napędu w kombajnie górniczym ścianowym
JP7007379B2 (ja) * 2017-06-30 2022-02-10 興和株式会社 医薬組成物
CN112592311B (zh) * 2021-01-03 2023-01-31 迪沙药业集团有限公司 一种硝苯地平a晶块状晶习及其控释片组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
US4571333A (en) * 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
IE59540B1 (en) * 1987-01-09 1994-03-09 Elan Corp Sustained release capsule or tablet formulation
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
GB8722306D0 (en) * 1987-09-22 1987-10-28 Aps Research Ltd Sustained-release formulation
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
YU45837B (sh) * 1988-01-18 1992-07-20 LEK TOVARNA FARMACEVTSKIH IN KEMIČKIH IZDELKOV d.d. Postopek za pripravo novega inkluzijskega kompleksa nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom
DE3814532A1 (de) * 1988-04-29 1989-11-09 Bayer Ag Dhp-retard-zubereitung
US4893393A (en) * 1988-10-25 1990-01-16 Marshall Ben C Pipe fitting assembly tool

Also Published As

Publication number Publication date
RU2122413C1 (ru) 1998-11-27
NO302216B1 (no) 1998-02-09
JPH061716A (ja) 1994-01-11
FI930657A0 (fi) 1993-02-15
HU9300424D0 (en) 1993-05-28
PL172361B1 (pl) 1997-09-30
IL104192A0 (en) 1993-05-13
CZ8193A3 (en) 1994-01-19
SK9793A3 (en) 1993-09-09
PL297747A1 (en) 1993-11-02
HUT64694A (en) 1994-02-28
NO930543D0 (no) 1993-02-16
CA2086989A1 (en) 1993-08-18
NO930543L (no) 1993-08-18
MX9300664A (es) 1994-07-29
US5439687A (en) 1995-08-08
FI930657A (fi) 1993-08-18
HU222252B1 (hu) 2003-05-28
CZ285177B6 (cs) 1999-06-16

Similar Documents

Publication Publication Date Title
US5439687A (en) Dosage forms having zero-order dihydropyridine calcium antagonist release
US6110494A (en) Cisapride mini-tablet formulations
US6027748A (en) Pharmaceutical tablet, completely coated, for controlled release of active principles that present problems of bio-availability linked to gastro-intestinal absorption
AU2003260336C1 (en) Sustained release formulations comprising lamotrigine
EP1576986A2 (en) Sustained-release tramadol formulations with 24-hour clinical efficacy
US20060127478A1 (en) Oral dosage formulation
KR101858797B1 (ko) 히드로모르폰 및 날록손을 포함하는 제약 조성물
WO2004037222A2 (en) Sustained-release tramadol formulations with 24-hour efficacy
AU2002322964B2 (en) Dosage forms having prolonged active ingredient release
MX2007001138A (es) Comprimido farmaceutico multicapa para la liberacion controlada de ingredientes activos con solubilidad muy dependiente del ph.
AU2002322964A1 (en) Dosage forms having prolonged active ingredient release
NZ539192A (en) Sustained release composition for oral administration of drugs
EP1633329A1 (en) Modified release formulations of selective serotonin re-uptake inhibitors
EP1594460A2 (en) Sustained-release tramadol formulations with 24-hour efficacy
CA2781826A1 (en) Controlled release pharmaceutical compositions of galantamine
WO2009027786A2 (en) Matrix dosage forms of varenicline
EP0557244B1 (en) Dosage forms having prolonged active-ingredient release
MXPA05004338A (es) Composiciones de liberacion sostenida que contienen alfuzosin.
Laicher et al. Influence of Tablet Formulation and Size on the in Vztro Sustained-Release Behavior of Metoprolol Tartrate from Hydrophilic Matrices
WO2008050188A2 (en) Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
WO2012053016A1 (en) Sustained release pharmaceutical compositions of donepezil
IE970001A1 (en) Sustained release cisapride mini-tablet formulation

Legal Events

Date Code Title Description
FF Patent granted
HP Change in proprietorship
KB Patent renewed
HC Change of name of proprietor(s)
EXP Patent expired